Investor Presentaiton

2023 Major Business Development Projects Out-licensing XKGbio accord The Evolution of Generics Boston Oncology™ In-licensing Sermonix Pharmaceuticals PT Kalbe Genexine Biologics (Contract signing date: 2023/08/25) Upfront payment US$7M Up to US$665M in Total* HANSIZHUANG (Serplulimab) Covering 12 countries in the Middle East and North Africa Accord Healthcare Limited Subsidiary of Intas Pharmaceuticals Limited (Contract signing date: 2023/10/27) Upfront payment up to €42M Up to €185M in Total HANSIZHUANG (Serplulimab) Covering 50+ countries in Europe and India Boston Oncology, LLC (Contract signing date: 2023/04/04) First time into the Saudi market HANLIKANG (Rituximab) Entered into NUPCO procurement marketplace in Saudi Arabia Sermonix Pharmaceuticals (Contract signing date: 2024/01/11) Milestone payment up to US$58M Lasofoxifene For breast cancer treatment Exclusive rights in China Expand HR+ breast cancer portfolio *The scope of the sales milestone payments will also include the previously authorized Southeast Asia 18 region, and the total sales milestone payments for the two authorizations will be no more than US$650 2024 Henlius. 2 Henlius

View entire presentation